Cardiff OncologyCRDF -2.31%49 PS Ratio is 141.11 as of Jul. 02, 2026, which is 18% below its 10-year median of 171.11. GuruFocus rates CRDF with a GF Score™ of 49/100 and a GF Value™ of $1.46 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 933 Biotechnology companies, Cardiff Oncology ranks worse than 87.35% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cardiff Oncology's share price is $1.27.
Cardiff Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01. Hence, Cardiff Oncology's PS Ratio for today is 141.11.
Good Sign:
Cardiff Oncology Inc stock PS Ratio (=144.44) is close to 2-year low of 134.44.
The historical rank and industry rank for Cardiff Oncology's PS Ratio or its related term are showing as below:
CRDF'
s PS Ratio Range Over the Past 10 Years
Min: 4.91 Med: 171.11 Max: 964.21
Current: 141.12
During the past 13 years, Cardiff Oncology's highest PS Ratio was 964.21. The lowest was 4.91. And the median was 171.11.
CRDF's PS Ratio is ranked worse than 87.35% of 933
companies
in the Biotechnology industry
Industry Median: 9.46
vs CRDF: 141.12
Cardiff Oncology Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Cardiff Oncology was -30.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -5.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -42.30% per year.
During the past 13 years, Cardiff Oncology's highest 3-Year average Revenue per Share Growth Rate was 15.90% per year. The lowest was -74.20% per year. And the median was -25.80% per year.
Back to Basics: PS Ratio
Cardiff Oncology (NAS:CRDF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cardiff Oncology PS Ratio Related Terms
Cardiff Oncology PS Ratio Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardiff Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cardiff Oncology's Share Price of today is $1.27. Cardiff Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cardiff Oncology (CRDF) has a PS Ratio of 141.11 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cardiff Oncology and its competitors. This is 18% below median its historical median of 171.11. Over the past decade, Cardiff Oncology's PS Ratio has ranged from 4.91 to 964.21. According to the industry distribution chart, Cardiff Oncology ranks #815 out of 933 companies in the Biotechnology industry, placing it in the top 87.4%.
Is Cardiff Oncology's PS Ratio too high?
Cardiff Oncology's current PS Ratio of 141.11 is 18% below median its 10-year median of 171.11. Over the past 10 years, this metric has ranged from a low of 4.91 to a high of 964.21. The Biotechnology industry median PS Ratio is 9.46. Cardiff Oncology's value of 141.11 is 1391.6% above this industry median. Based on the distribution chart, Cardiff Oncology ranks #815 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardiff Oncology has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's PS Ratio compare to MAIA and TELO?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #815 out of 933 companies for PS Ratio. This places Cardiff Oncology in the lower half of its industry. The industry median PS Ratio is 9.46. Cardiff Oncology's value of 141.11 is 1391.6% above this benchmark. Historically, Cardiff Oncology's own PS Ratio has ranged from 4.91 to 964.21 over the past decade. While the company's 10-year median is 171.11 vs. the industry median of 9.46, Cardiff Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.46, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current PS Ratio of 141.11 is 1391.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median PS Ratio is 9.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current PS Ratio is 141.11, which is 18% below median its own 10-year median of 171.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.46, compared to a current price of $1.27 — trading 13% below its estimated fair value. The current PS Ratio is 141.11, which is 18% below median its 10-year median of 171.11 and 1391.6% above the Biotechnology industry median of 9.46. Cardiff Oncology's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current PS Ratio is 141.11 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Oncology (CRDF) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued.
The current stock price of $1.27 is trading 13% below its estimated GF Value™ of $1.46.
GuruFocus considers Cardiff Oncology to be Modestly Undervalued.
Key valuation signals for CRDF:
PS Ratio: 141.11 (18% below median its 10-year median of 171.11)
GF Value™: $1.46 vs. price of $1.27 (13% below fair value)
Industry Position: 1391.6% above the Biotechnology median (#815 of 933)
No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
49GF Score
Get the complete analysis for CRDF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
